Ditchcarbon
  • Customers
  1. Organizations
  2. Swedish Orphan Biovitrum
Public Profile
Pharmaceutical Preparation Manufacturing
SE
updated 10 days ago

Swedish Orphan Biovitrum

Company website

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a leading biopharmaceutical company headquartered in Sweden (SE). Founded in 1991, Sobi has established itself as a key player in the biotechnology industry, focusing on rare diseases and specialty care. With a strong operational presence across Europe, North America, and the Asia-Pacific region, Sobi is dedicated to developing innovative therapies that address unmet medical needs. Sobi's core product portfolio includes treatments for haemophilia, inflammation, and genetic disorders, distinguished by their commitment to patient-centric solutions and advanced biopharmaceutical technologies. The company has achieved significant milestones, including strategic partnerships and a robust pipeline of therapies, solidifying its market position as a trusted provider in the rare disease sector. Sobi continues to make strides in improving patient outcomes and enhancing the quality of life for those affected by complex health conditions.

DitchCarbon Score

How does Swedish Orphan Biovitrum's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

54

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Swedish Orphan Biovitrum's score of 54 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.

74%

Let us know if this data was useful to you

Swedish Orphan Biovitrum's reported carbon emissions

In 2023, Swedish Orphan Biovitrum AB (Sobi) reported total carbon emissions of approximately 1551 tonnes CO2e, comprising 510 tonnes CO2e from Scope 1, 457 tonnes CO2e from Scope 2, and a significant 124,565 tonnes CO2e from Scope 3 emissions. This represents a notable increase in emissions compared to 2022, where total emissions were about 1351 tonnes CO2e, with Scope 1 at 495 tonnes CO2e, Scope 2 at 359 tonnes CO2e, and Scope 3 at 112,957 tonnes CO2e. Sobi has set ambitious climate commitments, aiming to reduce its operational greenhouse gas (GHG) footprint to net zero emissions by 2030 for both Scope 1 and Scope 2 emissions. Additionally, the company has committed to a 50% reduction in its operational GHG footprint from a 2015 baseline by 2025 for both Scope 1 and Scope 2 emissions. Furthermore, Sobi has established near-term targets to reduce absolute Scope 1 and 2 GHG emissions by 37.8% by FY2029, using FY2023 as the base year. The company also aims for 65% of its suppliers, by spend, to have science-based targets by FY2029. These targets align with industry standards and reflect Sobi's commitment to addressing climate change within the pharmaceutical and biotechnology sector. The emissions data and reduction initiatives are sourced directly from Swedish Orphan Biovitrum AB (publ) and are not cascaded from any parent organization.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2017201820192020202120222023
Scope 1
156,000
000,000
000,000
000,000
000,000
000,000
000,000
Scope 2
129,000
000,000
00,000
0,000,000
000,000
000,000
000,000
Scope 3
922,000
0,000,000
0,000,000
-
-
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Swedish Orphan Biovitrum's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Swedish Orphan Biovitrum is in SE, which has a very low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Swedish Orphan Biovitrum is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Glaxosmithkline

GB
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

UNO's

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Bioverativ Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Novartis Pharmaceuticals Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Sanofi

FR
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250808.1
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy